Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronavirus vaccine - Ufovax

Drug Profile

Coronavirus vaccine - Ufovax

Alternative Names: Novel coronavirus vaccine - Ufovax

Latest Information Update: 27 Mar 2020

At a glance

  • Originator Ufovax
  • Class Viral vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 24 Mar 2020 Early research in COVID-2019 infections in USA (Parenteral)
  • 24 Mar 2020 Ufovax plans preclinical and clinical trials for COVID-2019 infections

Development Overview

Introduction

A coronavirus vaccine is being developed by Ufovax (a spin-off company from Scripps Research), against the novel coronavirus SARS-CoV-2, using its one component self-assembling protein nanoparticle (1c-SApNP) vaccine platform technology. The vaccine prototype features SARS-CoV-2 protein spikes protruding from a protein nanoparticle scaffold. The nanoparticle vaccine would induce the immune system to rapidly generate antibodies to neutralise or deactivate the coronavirus, offering a recipient protection against the virus. The nanoparticle vaccine consists of self-assembling virus-like particles made from identical proteins. These proteins are synthesised through the insertion of a single plasmid encoding the relevant gene into a CHO or C1 (DYAI) host cell, followed by one-step expression and two subsequent purifications. Early research is underway in the US.

UFOTON platform technology involves creating virus-like particles (VLPs) that present highly stable uncleaved prefusion-optimised proteins, which mimic the native-like, closed state of a viral envelope spike before cell entry occurs, to elicit robust neutralising antibody responses in the host.

Company Agreements

Before March 2020, Ufovax acquired exclusive rights to develop and commercialise Scripps Research nanoparticle vaccine technology for certain vaccine targets. [1]

Patent Information

As of March 2020, Ufovax has patent protection for its one component self-assembling protein nanoparticle (1c-SApNP) vaccine platform technology in the US [1] .

Drug Properties & Chemical Synopsis

  • Route of administration Parenteral
  • Formulation unspecified
  • Class Viral vaccines, Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B (Viral Vaccines)

  • EPhMRA code

    J7E (Viral Vaccines)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections Prevention - Research USA Parenteral / unspecified Ufovax 24 Mar 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Ufovax Originator USA
Ufovax Owner USA
The Scripps Research Institute Technology Provider USA

Development History

Event Date Update Type Comment
24 Mar 2020 Patent Information Ufovax has patent protection for one component self-assembling protein nanoparticle (1c-SApNP) vaccine platform technology in USA [1] Updated 27 Mar 2020
24 Mar 2020 Phase Change Early research in COVID-2019 infections in USA (Parenteral) [1] Updated 27 Mar 2020
24 Mar 2020 Trial Update Ufovax plans preclinical and clinical trials for COVID-2019 infections [1] Updated 27 Mar 2020
23 Mar 2020 Licensing Status Ufovax in-licenses nanoparticle vaccine technology from The Scripps Research Institute before March 2020 [1] Updated 27 Mar 2020

References

  1. Ufovax successfully extended its Nanoparticle vaccine technology to SARS-CoV-2.

    Media Release
Back to top